OM vs. AORT, CDRE, ESTA, TNDM, FNA, BLFS, LQDA, SSII, PLSE, and INMD
Should you be buying Outset Medical stock or one of its competitors? The main competitors of Outset Medical include Artivion (AORT), Cadre (CDRE), Establishment Labs (ESTA), Tandem Diabetes Care (TNDM), Paragon 28 (FNA), BioLife Solutions (BLFS), Liquidia Technologies (LQDA), SS Innovations International (SSII), Pulse Biosciences (PLSE), and InMode (INMD). These companies are all part of the "medical equipment" industry.
Outset Medical vs. Its Competitors
Outset Medical (NASDAQ:OM) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.
In the previous week, Outset Medical and Outset Medical both had 2 articles in the media. Outset Medical's average media sentiment score of 0.93 beat Artivion's score of 0.10 indicating that Outset Medical is being referred to more favorably in the media.
Outset Medical currently has a consensus target price of $29.50, indicating a potential upside of 62.98%. Artivion has a consensus target price of $32.40, indicating a potential upside of 2.94%. Given Outset Medical's higher possible upside, analysts plainly believe Outset Medical is more favorable than Artivion.
Artivion has higher revenue and earnings than Outset Medical. Artivion is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.
86.4% of Artivion shares are owned by institutional investors. 2.4% of Outset Medical shares are owned by insiders. Comparatively, 7.6% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Artivion has a net margin of -5.49% compared to Outset Medical's net margin of -98.74%. Artivion's return on equity of 3.63% beat Outset Medical's return on equity.
Outset Medical has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.
Summary
Artivion beats Outset Medical on 11 of the 15 factors compared between the two stocks.
Get Outset Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Outset Medical Competitors List
Related Companies and Tools
This page (NASDAQ:OM) was last updated on 7/17/2025 by MarketBeat.com Staff
Free OM Stock Alerts